According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Immunotherapy radiotherapy combination is a key innovation area in immuno-oncology
Combining immunotherapy with radiotherapy is a strategy that has shown promising results in cancer treatment. Immunotherapy activates the immune system to recognize and attack cancer cells, while radiotherapy is used to damage cancer cells. When used together, they enhance each other’s effects and lead to better treatment outcomes.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of immunotherapy radiotherapy combination.
Key players in immunotherapy radiotherapy combination – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to immunotherapy radiotherapy combination
Source: GlobalData Patent Analytics
Immunolight is a biopharmaceutical company focused on advancing technologies to transform cancer treatment. The company developed a breakthrough technology that leverages the latest advances in energy transfer to establish high value innovations. The technology converts penetrating forms of energy, such as low dose X-Ray, into the ultraviolet part of the electromagnetic spectrum energies that can activate drugs inside the body, thereby triggering an immune response and creating a promising new approach to cancer treatment. Nanobiotix and Vertex Pharmaceuticals are some of the other key patent filers in immunotherapy radiotherapy combination.
In terms of application diversity, Aprogen Biologics leads the pack, while Merck and MetiMedi Pharmaceuticals stood in the second and third positions, respectively. By means of geographic reach, Les Laboratoires Servier held the top position, followed by HitGen and HitGen.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-oncology (IO).
#leading #innovators #immunotherapy #radiotherapy #combination #pharmaceutical #industry